HU
Humacyte, Inc.
HUMA · NASDAQ
$0.58 -0.82% (-$0.00)
1M -11.99%
Market Cap $99.1M
P/E Ratio -
Div. Yield -
ROE 938.20%
Bulios Fair Price
$0.3
48.5% downside
Current Price
$0.58
Undervalued Fair Value Overvalued
According to Bulios Fair Price, HUMA is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
3/9Valuation
32 /100
Expensive P/B 3.17x
P/S 46.73x
EV/EBITDA N/A
Growth
49 /100
Stable Book val. growth 70.15%
Rev. growth 9.20%
FCF growth N/A
Profitability
0 /100
Weak Net margin 4,560.82%
Op. margin 5,240.78%
FCF margin 4,599.72%
Quality
0 /100
Poor ROE 938.20%
ROA 70.05%
Asset turnover 0.02x
Debt
30 /100
High Current ratio 6.21x
Int. coverage -8.39x
Debt/Equity 2.12x
Stability
1 /100
Unstable EPS volatility 477.33%
Profitable years 0
Beta 2.45x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about HUMA
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Laura E. Niklason
Employees
184
Headquarters
Durham
Upcoming events
11 NOV
Earnings
Upcoming earnings report